JP2019517469A - ピプラドロールを用いる行動症候群の治療方法 - Google Patents

ピプラドロールを用いる行動症候群の治療方法 Download PDF

Info

Publication number
JP2019517469A
JP2019517469A JP2018561714A JP2018561714A JP2019517469A JP 2019517469 A JP2019517469 A JP 2019517469A JP 2018561714 A JP2018561714 A JP 2018561714A JP 2018561714 A JP2018561714 A JP 2018561714A JP 2019517469 A JP2019517469 A JP 2019517469A
Authority
JP
Japan
Prior art keywords
pipradolol
pharmaceutically acceptable
methods
disorder
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018561714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517469A5 (enExample
Inventor
マシュー・デューリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2019517469A publication Critical patent/JP2019517469A/ja
Publication of JP2019517469A5 publication Critical patent/JP2019517469A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2018561714A 2016-05-26 2017-05-25 ピプラドロールを用いる行動症候群の治療方法 Pending JP2019517469A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341855P 2016-05-26 2016-05-26
US62/341,855 2016-05-26
PCT/US2017/034443 WO2017205606A1 (en) 2016-05-26 2017-05-25 Methods of treating behavioral syndromes using pipradrol

Publications (2)

Publication Number Publication Date
JP2019517469A true JP2019517469A (ja) 2019-06-24
JP2019517469A5 JP2019517469A5 (enExample) 2020-07-02

Family

ID=60408578

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561714A Pending JP2019517469A (ja) 2016-05-26 2017-05-25 ピプラドロールを用いる行動症候群の治療方法

Country Status (10)

Country Link
US (3) US9827233B1 (enExample)
EP (1) EP3439657A4 (enExample)
JP (1) JP2019517469A (enExample)
KR (1) KR20190013737A (enExample)
CN (1) CN109414435A (enExample)
AU (1) AU2017268795A1 (enExample)
CA (1) CA3025473A1 (enExample)
IL (1) IL262986A (enExample)
MX (1) MX2018013973A (enExample)
WO (1) WO2017205606A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391708B (es) 2015-07-17 2025-03-21 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo con gaboxadol.
US9351968B1 (en) * 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
JP2019517469A (ja) * 2016-05-26 2019-06-24 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ピプラドロールを用いる行動症候群の治療方法
US20190076409A1 (en) * 2017-09-12 2019-03-14 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of narcolepsy
KR20210062662A (ko) 2018-09-20 2021-05-31 오비드 테라퓨틱스 인크. 투렛 증후군, 틱들 및 말더듬의 치료를 위한 가복사돌의 사용
AU2019384157A1 (en) 2018-11-21 2021-06-17 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
KR20210105387A (ko) 2018-12-17 2021-08-26 오비드 테라퓨틱스 인크. 비-24 시간 수면-각성 장애의 치료를 위한 가복사돌의 사용
GB201911056D0 (en) * 2019-08-02 2019-09-18 Sanchez Hector Mario Treatment of ADD/ADHD
KR20230028244A (ko) 2020-05-20 2023-02-28 썰테고 테라퓨틱스 아이엔씨. 고리 중수소화 가복사돌 및 정신 장애의 치료를 위한 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518027A (ja) * 2007-02-07 2010-05-27 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド Ａｄｈｄの治療

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US5650521A (en) * 1995-12-29 1997-07-22 Guilford Pharmaceuticals Inc. Pyrrolidine derivatives
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
CN102123586A (zh) 2008-07-18 2011-07-13 法弗根股份有限公司 治疗超重或肥胖受试者的方法
FR2935611B1 (fr) 2008-09-10 2010-10-15 Commissariat Energie Atomique Utilisation d'agents anti-connexines pour moduler l'effet therapeutique de molecules psychotropes
US20100260844A1 (en) * 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US20120302590A1 (en) * 2009-08-13 2012-11-29 The General Hospital Corporation Methods and compositions to prevent addiction
EP2575853B1 (en) 2010-05-25 2016-08-24 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient
US9028868B2 (en) * 2011-03-23 2015-05-12 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
JP2019517469A (ja) * 2016-05-26 2019-06-24 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ピプラドロールを用いる行動症候群の治療方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518027A (ja) * 2007-02-07 2010-05-27 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド Ａｄｈｄの治療

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TOXICOLOGY LETTERS, vol. 212, JPN6021022379, 2012, pages 57 - 60, ISSN: 0004695754 *

Also Published As

Publication number Publication date
CA3025473A1 (en) 2017-11-30
CN109414435A (zh) 2019-03-01
AU2017268795A1 (en) 2018-11-22
MX2018013973A (es) 2019-03-28
US20170340619A1 (en) 2017-11-30
EP3439657A4 (en) 2019-12-18
US20180036298A1 (en) 2018-02-08
KR20190013737A (ko) 2019-02-11
IL262986A (en) 2018-12-31
US9827233B1 (en) 2017-11-28
EP3439657A1 (en) 2019-02-13
WO2017205606A1 (en) 2017-11-30
US10493069B2 (en) 2019-12-03
US20190076415A1 (en) 2019-03-14

Similar Documents

Publication Publication Date Title
JP2019517469A (ja) ピプラドロールを用いる行動症候群の治療方法
JP6119068B2 (ja) 認知障害の処置に有用なα−アミノアミド誘導体
US9913833B2 (en) Methods of treating developmental disorders using pipradrol
US9682069B2 (en) Methods of treating Dravet syndrome
US20220023316A1 (en) Methods for the treatment of depression
US20120046302A1 (en) Methods of treating cns disorders
WO2010126527A1 (en) Methods of treating cns disorders
HK40003594A (en) Methods of treating behavioral syndromes using pipradrol
HK1170429B (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220201